Literature DB >> 31092579

The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.

Adriana Weinberg1, Lei Pang2, Michael J Johnson3, Yupanqui Caldas3, Alice Cho3, Adriana Tovar-Salazar3, Jennifer Canniff3, Kenneth E Schmader4, Zoran Popmihajlov2, Myron J Levin3.   

Abstract

Older age is associated with increased infectious morbidity and decreased immune responses to vaccines, but the mechanisms that mediate this effect are incompletely understood. The efficacy and immunogenicity of the live attenuated zoster vaccine (ZVL) have a very-well-described negative association with the age of the vaccinee. In a study of 600 ZVL recipients 50 to >80 years of age, we investigated immunological factors that might explain the effect of age on the immunogenicity of ZVL. Using FluoroSpot assays and flow cytometry, we determined that varicella-zoster virus (VZV)-specific peak T helper 1 (VZV-Th1) responses to ZVL were independently predicted by prevaccination VZV-Th1 responses, regulatory T cells (Treg), and PD1-expressing immune checkpoint T cells (Tcheck) but not by the age of the vaccinee. Persistence of VZV-Th1 1 year after vaccination was independently predicted by the factors mentioned above, by peak VZV-Th1 responses to ZVL, and by the age of the vaccinee. We further demonstrated by ex vivo blocking experiments the mechanistic role of PD1 and CTLA4 as modulators of decreased VZV-Th1 responses in the study participants. VZV-specific cytotoxic T cell (VZV-CTL) and T follicular helper responses to ZVL did not correlate with age, but similar to other Th1 responses, VZV-CTL peak and baseline responses were independently correlated. These data expand our understanding of the factors affecting the magnitude and kinetics of T cell responses to ZVL in older adults and show the importance of prevaccination Treg and Tcheck in modulating the immunogenicity of ZVL. This presents new potential interventions to increase vaccine responses in older adults.IMPORTANCE Vaccination is the most effective method to protect older adults against viral infections. However, the immunogenicity of viral vaccines in older adults is notoriously poor. The live attenuated zoster vaccine (ZVL) provides the best example of a gradual decrease of vaccine immunogenicity with every 10-year age increase above 50 years. Here we show that the abundance of regulatory T cells before vaccine administration to older adults has a significant inhibitory effect on immune responses to ZVL and, together with baseline immunity to varicella-zoster virus, explains the effect of age on the immunogenicity of ZVL. Moreover, in vitro blockade of regulatory T cell mechanisms of action with biologic modulators restores immune responses to varicella-zoster virus in vaccinees. Collectively, these observations suggest that immune modulators that block regulatory T cell activity may increase responses to viral attenuated vaccines in older adults.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  cell-mediated immunity; herpes zoster; zoster vaccine live

Mesh:

Substances:

Year:  2019        PMID: 31092579      PMCID: PMC6639287          DOI: 10.1128/JVI.00305-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

Review 1.  Inflamm-aging. An evolutionary perspective on immunosenescence.

Authors:  C Franceschi; M Bonafè; S Valensin; F Olivieri; M De Luca; E Ottaviani; G De Benedictis
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

2.  Immune response to diphtheria booster vaccine in the Baltic states.

Authors:  T Rønne; R Valentelis; S Tarum; A Griskevica; C H Wachmann; H Aggerbeck; A M Plesner; K G Hansen; P Ricks
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

3.  Ageing and immunity: addressing immune senescence to ensure healthy ageing.

Authors:  Diana Boraschi; Giuseppe Del Giudice; Catherine Dutel; Bernard Ivanoff; Rino Rappuoli; Beatrix Grubeck-Loebenstein
Journal:  Vaccine       Date:  2010-04-01       Impact factor: 3.641

4.  Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Authors:  Adriana Weinberg; Ann A Lazar; Gary O Zerbe; Anthony R Hayward; Ivan S F Chan; Rupert Vessey; Jeffrey L Silber; Rob R MacGregor; Kenny Chan; Anne A Gershon; Myron J Levin
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

Review 5.  Antibody response to influenza vaccination in the elderly: a quantitative review.

Authors:  Katherine Goodwin; Cécile Viboud; Lone Simonsen
Journal:  Vaccine       Date:  2005-09-19       Impact factor: 3.641

6.  Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity.

Authors:  Massimo De Martinis; Claudio Franceschi; Daniela Monti; Lia Ginaldi
Journal:  FEBS Lett       Date:  2005-04-11       Impact factor: 4.124

7.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

8.  Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.

Authors:  J G Smith; X Liu; R M Kaufhold; J Clair; M J Caulfield
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

9.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

10.  Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

Authors:  M J Levin; M N Oxman; J H Zhang; G R Johnson; H Stanley; A R Hayward; M J Caulfield; M R Irwin; J G Smith; J Clair; I S F Chan; H Williams; R Harbecke; R Marchese; S E Straus; A Gershon; A Weinberg
Journal:  J Infect Dis       Date:  2008-03-15       Impact factor: 5.226

View more
  11 in total

1.  Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence.

Authors:  Michael J Johnson; Cuining Liu; Debashis Ghosh; Nancy Lang; Myron J Levin; Adriana Weinberg
Journal:  J Infect Dis       Date:  2022-04-19       Impact factor: 7.759

Review 2.  Aging and Options to Halt Declining Immunity to Virus Infections.

Authors:  Miguel Ángel Palacios-Pedrero; Albert D M E Osterhaus; Tanja Becker; Husni Elbahesh; Guus F Rimmelzwaan; Giulietta Saletti
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

3.  The frequency of interleukin-1β-producing monocytes is significantly associated with varicella-zoster responses of nursing home residents.

Authors:  E Picard; D M E Bowdish; J E McElhaney; G Pawelec; M Loeb; C P Verschoor
Journal:  Clin Exp Immunol       Date:  2021-04-04       Impact factor: 5.732

4.  Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.

Authors:  Eli Muchtar; Amber B Koehler; Michael J Johnson; Kari G Rabe; Wei Ding; Timothy G Call; Jose F Leis; Saad S Kenderian; Suzanne R Hayman; Yucai Wang; Paul J Hampel; Matthew A Holets; Heather C Darby; Susan L Slager; Neil E Kay; Congrong Miao; Jennifer Canniff; Jennifer A Whitaker; Myron J Levin; D Scott Schmid; Richard B Kennedy; Adriana Weinberg; Sameer A Parikh
Journal:  Am J Hematol       Date:  2021-11-05       Impact factor: 13.265

Review 5.  Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives.

Authors:  Angelika Wagner; Birgit Weinberger
Journal:  Front Immunol       Date:  2020-04-23       Impact factor: 7.561

Review 6.  Influence of immune aging on vaccine responses.

Authors:  Claire E Gustafson; Chulwoo Kim; Cornelia M Weyand; Jörg J Goronzy
Journal:  J Allergy Clin Immunol       Date:  2020-05       Impact factor: 10.793

Review 7.  Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly.

Authors:  Branca Pereira; Xiao-Ning Xu; Arne N Akbar
Journal:  Front Immunol       Date:  2020-10-14       Impact factor: 7.561

8.  Ageing of Immune System and Response to a Live-Attenuated Herpes Zoster Vaccine in Lung Transplant Candidates.

Authors:  Lei Wang; Erik A M Verschuuren; Davy Paap; Christien Rondaan; Elisabeth Raveling-Eelsing; Siqi Liu; Johanna Westra; Nicolaas A Bos
Journal:  Vaccines (Basel)       Date:  2021-02-28

Review 9.  Predictive Markers of Immunogenicity and Efficacy for Human Vaccines.

Authors:  Matthieu Van Tilbeurgh; Katia Lemdani; Anne-Sophie Beignon; Catherine Chapon; Nicolas Tchitchek; Lina Cheraitia; Ernesto Marcos Lopez; Quentin Pascal; Roger Le Grand; Pauline Maisonnasse; Caroline Manet
Journal:  Vaccines (Basel)       Date:  2021-06-01

Review 10.  Current Challenges in Vaccinology.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Peter Palese; Gregory A Poland
Journal:  Front Immunol       Date:  2020-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.